John Vito Antonucci, MD is a board certified radiation oncologist serving Southeast Michigan. He was selected to the National Medical Honor Society, Alpha Omega Alpha, at Tufts University School of Medicine. He served as the chief resident in radiation oncology at William Beaumont Hospital and was recognized locally and nationally for his research in prostate and breast cancer. Dr. Antonucci has received specialty training in stereotactic radiosurgery (SRS) for the treatment of malignant and benign tumors of the brain and spine. He holds privileges to perform Gamma Knife SRS procedures at the Karmanos Cancer Institute and William Beaumont Hospital. In addition, he offers patients all aspects of stereotactic body radiation therapy (SBRT), an ablative procedure for malignant lesions throughout the body. He treats a wide range of diseases, including breast, lung, gastrointestinal, lymphoma, prostate and bladder cancers.
Career Positions
Current position(s)
- GenesisCare - Radiation Oncologist, Pontiac, MI,
Past position(s)
- William Beaumont Hospital - Attending Physician, Royal Oak, MI
Education
Universities
- College of the Holy Cross, BA, Biology, Worcester, MA
- Tufts University School of Medicine, Boston, MA
Residencies
- William Beaumont Hospital, Radiation Oncology, Chief Resident, Royal Oak, MI
Internships
- William Beaumont Hospital, Transitional Internship, Royal Oak, MI
Expertise And Interests
Interests
- Prostate, Breast, Lung, Gastrointestinal, Central Nervous System, Head & Neck Hematologic Malignancies
Professional associations
Accomplishments
Awards and honors
- Alpha Omega Alpha, 49th ASTRO Resident Poster Recognition Award, First Prize for Delmar H. Mahrt MD Resident Research Competition, 26th American Brachytherapy Society Resident Travel Grant Award, David F. Noonan Research Fellowship Award
Clinical studies
Primary Objective - To determine whether men with NCCN high risk prostate cancer who are in the lower 2/3 of Decipher genomic risk (< 0.85) can be treated with 12 months ADT plus RT instead of 24 months ADT+RT and experience non-inferior metastasis-free survival.
View Study